ChemotherapyFDA-approvedSecond-line
FOLFIRI
Generic name: irinotecan, fluorouracil, leucovorin
How it works
FOLFIRI is a combination chemotherapy regimen that works by interfering with DNA replication and cell division in cancer cells, ultimately leading to cell death.
Cancer types
Efficacy
Studies show that FOLFIRI can improve overall survival in patients with metastatic colorectal cancer, with median survival ranging from 12 to 18 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Combining Nanoparticles and Medication to Boost Pancreatic Cancer Treatment | Pancreatic Cancer | animal-study | — | Source → |
| Combining Cancer Drugs Improves Immune Response in Lab Experiments | Colorectal Cancer | lab-study | This neutrophil-based formulation resulted in a >4-fold increase in the ratios of the amount of both IRI and GAL accumulated in tumors to the dosage administration. | Source → |
| Engineered Nanocarriers Improve Irinotecan Delivery for Colon Cancer | Colorectal Cancer | lab-study | The P-DSPE-PEG-Ir LP exhibited significant tumor growth delay as compared to untreated and blank formulation-treated groups. | Source → |
| New Treatment Combination Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The 6-month progression-free survival rate was 58.8%. | Source → |
| New Treatment Shows Promise for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | The use of nal-IRI resulted in significantly improved progression-free survival (pooled mean difference=1.01 months, 95% confidence interval [CI]=0.97-1.05, p<0.01) and overall survival (pooled mean difference=0.29 months, 95%CI=0.18-0.39, p<0.01), as well as significantly better overall response rate (pooled odds ratio=2.06, 95%CI=1.30-3.27, p=0.002) compared to other second-line regimens. | Source → |
| Comparing Cancer Treatments for Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The expected survival times were 20.9 months for FOLFIRI, 29.9 months for Bmab, 27.8 months for Cmab, and 22.6 months for Pmab. | Source → |
| New Study Helps Optimize Chemotherapy for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | — | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Liposomal Irinotecan in Biliary Tract Cancer: A Meta-Analysis | Pancreatic Cancer | meta-analysis | The combination therapy exhibited a statistically significant decrease in the risk of progression (hazard ratio 0.70; 95% confidence interval 0.50-0.97) | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.